- Home
- KPRX vs NXL Comparison
KPRX vs NXL Comparison
Compare KPRX & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- NXL
- Stock Information
- Founded
- KPRX 1998
- NXL 2010
- Country
- KPRX United States
- NXL United States
- Employees
- KPRX N/A
- NXL N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NXL Medical Specialities
- Sector
- KPRX Health Care
- NXL Health Care
- Exchange
- KPRX Nasdaq
- NXL Nasdaq
- Market Cap
- KPRX 10.0M
- NXL 10.0M
- IPO Year
- KPRX N/A
- NXL 2022
- Fundamental
- Price
- KPRX $3.91
- NXL $3.16
- Analyst Decision
- KPRX Strong Buy
- NXL Hold
- Analyst Count
- KPRX 1
- NXL 1
- Target Price
- KPRX $10.00
- NXL N/A
- AVG Volume (30 Days)
- KPRX 54.6K
- NXL 445.0K
- Earning Date
- KPRX 11-08-2024
- NXL 11-08-2024
- Dividend Yield
- KPRX N/A
- NXL N/A
- EPS Growth
- KPRX N/A
- NXL N/A
- EPS
- KPRX 1.69
- NXL N/A
- Revenue
- KPRX $16,020,000.00
- NXL $162,078.00
- Revenue This Year
- KPRX N/A
- NXL $56.86
- Revenue Next Year
- KPRX N/A
- NXL $167.44
- P/E Ratio
- KPRX $2.31
- NXL N/A
- Revenue Growth
- KPRX N/A
- NXL 26.00
- 52 Week Low
- KPRX $3.00
- NXL $0.25
- 52 Week High
- KPRX $8.98
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- KPRX 60.98
- NXL 51.05
- Support Level
- KPRX $3.10
- NXL $2.55
- Resistance Level
- KPRX $4.00
- NXL $3.11
- Average True Range (ATR)
- KPRX 0.25
- NXL 0.32
- MACD
- KPRX 0.02
- NXL 0.03
- Stochastic Oscillator
- KPRX 90.00
- NXL 70.71
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.